Literature DB >> 34743297

Pleiotropic predisposition to Alzheimer's disease and educational attainment: insights from the summary statistics analysis.

Alexander M Kulminski1, Elena Loiko2, Yury Loika2, Irina Culminskaya2.   

Abstract

Epidemiological studies report beneficial associations of higher educational attainment (EDU) with Alzheimer's disease (AD). Prior genome-wide association studies (GWAS) also reported variants associated with AD and EDU separately. The analysis of pleiotropic associations with these phenotypes may shed light on EDU-related protection against AD. We performed pleiotropic meta-analyses using Fisher's method and omnibus test applied to summary statistics for single nucleotide polymorphisms (SNPs) associated with AD and EDU in large-scale univariate GWAS at suggestive-effect (5 × 10-8 < p < 0.1) and genome-wide (p ≤ 5 × 10-8) significance levels. We report 53 SNPs that attained p ≤ 5 × 10-8 at least in one of the pleiotropic meta-analyses and were reported in the univariate GWAS at 5 × 10-8 < p < 0.1. Of them, there were 46 pleiotropic SNPs according to Fisher's method. Additionally, Fisher's method identified 25 of 206 SNPs with pleiotropic effects, which attained p ≤ 5 × 10-8 in the univariate GWAS. We showed that a large fraction of the pleiotropic associations was affected by a counterintuitive phenomenon of antagonistic genetic heterogeneity, which explains the increase, rather than decrease, of the significance of the pleiotropic associations in the omnibus test. Functional enrichment analysis showed that apart from cancers, gene set harboring the non-pleiotropic SNPs was characterized by late-onset AD and neurodevelopmental disorders. The pleiotropic gene set was characterized by a broad spectrum of progressive neurological and neuromuscular diseases and immune-mediated conditions, including progressive motor neuropathy, multiple sclerosis, Parkinson's disease, and severe AD. Our results suggest that disentangling genes harboring variants with and without pleiotropic associations with AD and EDU is promising for dissecting heterogeneity in biological mechanisms of AD.
© 2021. The Author(s), under exclusive licence to American Aging Association.

Entities:  

Keywords:  Aging; Alzheimer’s disease; Complex traits; Education; Heterogeneity; Pleiotropy

Mesh:

Year:  2021        PMID: 34743297      PMCID: PMC8572080          DOI: 10.1007/s11357-021-00484-1

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.713


Background

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder, which prevalence and incidence dramatically increase with age [1]. Studies also report no change or even declining trend of prevalence and incidence in developed countries during recent decades owing to, in part, higher educational attainment (EDU) and the progress in controlling cardiovascular risk factors [2, 3]. The burden of AD, however, is projected to increase over time due to population aging and potential adverse trends of AD risk factors such as obesity and diabetes [4, 5]. This epidemiological evidence suggests that interventions aiming to improve the protective effect of AD modifiable risk factors might be a promising strategy in AD prevention and reducing its burden [6]. The association of higher EDU (i.e., more years of schooling) with a lower risk of AD is among the most robust findings in AD research [6, 7]. Despite that, the nature of connections between EDU and AD (i.e., causal, correlative, confounding) remains poorly understood. One hypothesis is that EDU helps build and maintain the cognitive reserve, and, therefore, education is considered a proxy of cognitive reserve [8]. This hypothesis leverages the observations that age-related brain damage does not seem to be directly linked to the clinical manifestation of the disease [9-11]. People with a greater cognitive reserve may better tolerate pathological changes due to preexisting connections between neurons ensuring higher cognitive processing and compensatory adaptation and creating new connections [12]. Accordingly, the cognitive reserve can be a plausible mechanism of cognitive resilience [13]. The cognitive reserve hypothesis suggests the existence of biological mechanisms, which can create stronger connections between the neurons and ascertaining synaptic plasticity. If EDU can affect AD development through a cognitive reserve or any other education-related mechanism(s), there should be a common genetic basis of EDU and AD. For example, this basis can be represented by pleiotropic genes, which can shed light on a mechanism involved in the protection of EDU against AD development. Because AD is a heterogeneous condition, the cognitive reserve does not exhaust all potential factors associated with its pathogenesis. For example, emerging research suggests that overall health and aging-related processes quantified using a frailty index approach [14] may be important factors contributing to the relationship between AD pathology and cognition both as modulators and in an independent manner [15, 16]. These latent factors may partly explain accumulating observations of discrepancies in correlations between AD manifestation, AD biomarkers, and neuropathological changes [16]. Overall, it is increasingly recognized that AD should be considered a condition determined by multiple, likely interacting, pathophysiological processes. The view on AD as “a multiply determined condition” [16] warrants exploring new approaches in the analyses of genetic predisposition to AD, particularly in the case of pleiotropy, herein referenced to as pleiotropic predisposition. These approaches should recognize the complex roles of genetic factors in heterogeneous, age-related traits such as AD in both univariate and pleiotropic contexts. This recognition can be beneficial in identifying conventional pleiotropic associations with age-related traits and unconventional ones, such as antagonistic genetic heterogeneity characterized by discrepancies between the associations of a genetic variant with different traits and correlation between them [17, 18]. Here, we leveraged a pleiotropic meta-analysis using Fisher’s method and omnibus test [18] applied to publicly available summary statistics (effect sizes, standard errors, and p values) for single nucleotide polymorphisms (SNPs) from large-scale univariate GWAS of AD [19] and EDU [20]. We examined pleiotropic predisposition to these outcomes and evaluated functional roles of gene sets harboring pleiotropic and non-pleiotropic SNPs.

Methods

Publicly available summary statistics

Summary statistics for AD [19] and EDU [20] were provided for 7,055,881 and 8,146,840 SNPs, respectively, whose minor allele frequency (MAF) was larger than 1%. There were 6,814,698 overlapping SNPs between these GWAS. After excluding 695 multi-allelic and palindromic SNPs, the analyzed set was reduced to 6,814,003 SNPs. Further analyses focused on SNPs, which attained and did not attain the genome-wide (GW) significance (p < 5 × 10−8) separately in the published GWAS. The GW significant set included 957 SNPs in 42 loci from the AD GWAS and 4,747 SNPs in 185 loci from the EDU GWAS, totaling 5,704 SNPs. There were no SNPs that attained GW significance in both univariate GWAS simultaneously. The set of SNPs that did not achieve GW significance in either univariate GWAS included 6,808,299 SNPs.

Pleiotropic meta-analysis

We used two types of tests to perform a pleiotropic meta-analysis of AD and EDU. The first test used Fisher’s method [21]. It combines p values across phenotypes, assuming that the combining statistics are independent. Although this test is practical, its disadvantage is that it neither considers the directions of the associations with outcomes to be combined nor the potential correlation between them. To examine the potential roles of these two factors, we used a more comprehensive omnibus test [22-24]. In this study, we have summary statistics from univariate GWAS for two outcomes (K = 2), AD and EDU, for each SNP to test for pleiotropy. Then, the omnibus test in this two-dimensional case for an SNP j reads (index j is omitted): Here is a z-score vector of associations of an SNP with outcomes and Σ is the correlation matrix of the z-scores or outcomes [23, 24]. The z-score for the associations with AD was defined as , where β is the estimated effect size and σ is the corresponding standard error of an association of a SNP with AD. GWAS of EDU [20] reported truncated estimates of the effect sizes and standard errors. More accurate estimation of the z-score for EDU was evaluated using the reported p values given the sign of the corresponding effect size. Under the null hypothesis (  0), the test statistic follows a chi-square distribution with K degrees of freedom: from which we obtained a combined p value for this pleiotropic test. As follows from Equation (1) above, the correlation between phenotypes may not necessary attenuate the significance of the pleiotropic associations in the case when , > 0, but also strengthen them when , < 0. The latter implies a counterintuitive phenomenon of antagonistic genetic heterogeneity, which is common in the genetics of heterogeneous traits [17, 18]. The increase of significance (i.e., a decrease of p value) is due to a mismatch of the signs of the associations with complex outcomes (i.e., the sign of the product ) and correlation between them (i.e., Σ21, Σ12).

Correlation

Correlation matrix Σ was constructed [24] by evaluating Pearson correlation coefficients between the AD and EDU phenotypes available in the Framingham Heart Study (FHS) parental and offspring cohorts [25], Cardiovascular Health Study (CHS) [26], and the National Institute on Aging (NIA) Late-Onset Alzheimer Disease Family Study (LOADFS) [27]. AD was categorized as 1 and 0 for the AD-affected and unaffected subjects, respectively. EDU variable was coded as years of education. The correlation coefficients between these phenotypes were evaluated in each cohort separately, r = −0.03 in CHS, r = −0.03 in FHS, and r = −0.31 in LOADFS. The large magnitude of r in the LOADFS is likely because of the AD case-control design of this study, which is different from the population/community-based longitudinal designs of the FHS and CHS cohorts. We also evaluated Pearson correlation coefficient between AD and EDU using summary statistics from the published AD and EDU GWAS, r = −0.03. Given these estimates, we constructed two 2-by-2 correlation matrices Σ with off-diagonal values r = −0.03 and r = −0.30.

Pleiotropic associations

Fisher’s method and the omnibus test can both be used to identify pleiotropic associations. An advantage of the omnibus test is that it takes into account correlation between phenotypes (see above). Correlation can be a sensitive parameter in the omnibus test [17, 18] and its accurate evaluation is desirable. This evaluation requires more detailed (individual- or study-level) data than those available from the published summary statistics. Because Fisher’s method does not rely on correlation, it was our primary tool to define the pleiotropic effects. Using this method, the pleiotropic effect can be naturally defined when the pleiotropic p value from Fisher’s method is smaller than the p value from either AD or EDU univariate GWAS. This definition has a clear interpretation because Fisher’s method provides the probability of an event. When Fisher’s p value from a pleiotropic analysis is smaller than p values from univariate analyses, this implies that the probability of the pleiotropic association with multiple phenotypes is larger than those of each of these phenotypes separately. Fisher’s method and the omnibus test penalize the estimates of p values for testing multiple phenotypes by increasing the number of degrees of freedom for χ. Therefore, the traditional GW level of significance, p = 5 × 10−8, remains relevant and it was used for reporting GW significance attained in at least one pleiotropic meta-analysis using Fisher’s method and/or omnibus test.

Index SNPs

We selected one index SNP per gene or gene cluster if genes overlap. The index SNP was defined as an SNP with the smallest p value attained in an omnibus test. We reported SNPs, which might be in the same locus (distinct loci are determined if they are separated by more than 1M base pairs or they are on different chromosomes), but were mapped to different genes because associations with AD and EDU may not be due to the same genes.

Gene mapping and functional enrichment analysis

SNPs were mapped to genes using variant effect predictor from Ensembl and the NCBI SNP database (assembly GRCh37.p13). For SNPs that were not in protein-coding regions, we selected the closest protein-coding gene(s). The vast majority of genes were within ±100K base pairs from the index SNP. Functional enrichment analysis was performed using the core analysis function available in the Ingenuity Pathway Analysis (IPA) tool (www.qiagenbioinformatics.com) to gain insights into potential underlying biological mechanisms of the observed associations.

Results

Pleiotropic associations for SNPs, which did not attain GW significance in the univariate GWAS of EDU or AD

First, we performed a pleiotropic meta-analysis of summary statistics for the associations, which did not attain GW significance with AD [19] or EDU [20]. This analysis identified 53 SNPs, which were associated with either AD or EDU at 5 × 10−8 < p < 0.1, but they attained GW significance (p ≤ 5 × 10−8) in at least one pleiotropic test, i.e., Fisher’s method and/or omnibus test (Table 1 and Supplementary Table S1).
Table 1.

Genome-wide significant pleiotropic associations for SNPs, which did not attain genome-wide significance in the univariate GWAS of education or Alzheimer’s disease.

Locus-SNP informationEducationAlzheimer’s diseasePleiotropic analysis
SNPChrPos, kbA1EAFβEDUPEDUβADPADPFisherPOmni1POmni2PltAH
rs237436194,039T0.23−0.0153.37E-07−0.0508.56E-035.95E-084.63E-081.66E-10YesYes
rs24774321112,185A0.570.0121.14E-060.0343.99E-028.12E-076.38E-078.12E-09YesYes
rs1138305671207,677T0.200.0067.03E-020.0991.34E-061.61E-061.24E-062.44E-08NoYes
rs17504614251,080T0.820.0156.37E-07−0.0632.78E-033.74E-087.23E-081.20E-06YesNo
rs268134265,608A0.240.0151.91E-070.0486.65E-032.73E-082.09E-085.58E-11YesYes
rs101721132226,618T0.25−0.0146.30E-07−0.0441.31E-021.62E-071.28E-076.89E-10YesYes
rs1603981325,185A0.18−0.0154.48E-06−0.0501.44E-021.13E-069.50E-078.74E-09YesYes
rs17785248347,673A0.750.0141.28E-060.0318.79E-021.91E-061.45E-063.35E-08NoYes
rs1665982347,905A0.27−0.0144.25E-07−0.0383.24E-022.63E-072.02E-071.80E-09YesYes
rs72624911349,065T0.040.0321.22E-060.1653.19E-027.02E-075.56E-076.18E-09YesYes
rs10446472351,294A0.16−0.0171.40E-06−0.0824.52E-021.11E-068.78E-071.27E-08YesYes
rs7307960941,750A0.170.0172.99E-060.0513.20E-021.65E-061.34E-061.83E-08YesYes
rs10012882466,243T0.98−0.0311.10E-04−0.1771.01E-031.90E-061.72E-061.08E-08YesYes
rs10071982562,703A0.430.0123.88E-060.0372.09E-021.41E-061.17E-061.29E-08YesYes
rs76154441616,763T0.96−0.0331.21E-06−0.0786.48E-021.36E-061.05E-061.90E-08NoYes
rs139325018632,109A0.86−0.0131.59E-04−0.0799.63E-042.56E-062.34E-061.63E-08YesYes
rs140677956632,340T0.45−0.0126.65E-05−0.0672.40E-043.02E-072.63E-077.72E-10YesYes
rs114684261632,395T0.71−0.0089.54E-03−0.0988.13E-081.70E-081.27E-083.46E-11YesYes
rs115643100632,410T0.100.0133.50E-030.1063.89E-052.28E-062.05E-061.61E-08YesYes
rs9272666632,609T0.400.0113.14E-040.1048.24E-075.96E-094.61E-093.62E-12YesYes
rs75351515632,635A0.47−0.0131.25E-05−0.0856.77E-051.85E-081.49E-081.46E-11YesYes
rs115795926632,682A0.71−0.0105.04E-04−0.0911.43E-061.59E-081.26E-081.47E-11YesYes
rs9357551647,606T0.270.0055.98E-020.0891.15E-061.20E-069.30E-071.58E-08NoYes
rs17616086109,518A0.410.0114.83E-060.0501.28E-031.23E-071.02E-072.68E-10YesYes
rs153382772,074T0.210.0151.28E-060.0394.97E-021.12E-068.76E-071.33E-08YesYes
rs695200678,134T0.850.0182.53E-07−0.0677.17E-033.83E-086.81E-088.27E-07YesNo
rs127059797114,335T0.44-0.0111.06E-05−0.0401.38E-022.45E-062.11E-062.34E-08YesYes
rs536332827,476A0.550.0054.22E-020.0832.07E-071.71E-071.27E-071.17E-09YesYes
rs35927132828,683T0.160.0147.85E-050.0672.08E-032.72E-062.47E-061.90E-08YesYes
rs12675931891,901T0.730.0111.83E-040.0671.85E-046.16E-075.46E-072.09E-09YesYes
rs2631024891,996A0.27−0.0104.72E-04−0.0633.50E-042.74E-062.52E-061.75E-08YesYes
rs1200629693,142C0.340.0122.65E-060.0315.39E-022.39E-061.91E-063.58E-08YesYes
rs79124951011,719A0.53−0.0081.96E-03−0.0631.07E-043.44E-063.15E-062.59E-08YesYes
rs1221934610104,657T0.690.0149.55E-080.0334.93E-029.50E-086.87E-086.09E-10YesYes
rs46002111124,725T0.79−0.0142.79E-06−0.0394.26E-022.02E-061.63E-062.63E-08YesYes
rs2860431185,073T0.98−0.0193.67E-02-0.2555.79E-063.48E-062.89E-064.98E-08YesYes
rs95095581321,697T0.40−0.0095.29E-04−0.0645.16E-044.40E-064.09E-063.42E-08YesYes
rs456183321464,906T0.240.0133.19E-060.0402.58E-021.42E-061.17E-061.41E-08YesYes
rs287305491464,962A0.67−0.0131.07E-06−0.0316.11E-021.14E-068.82E-071.50E-08NoYes
rs71606341465,001A0.330.0139.27E-070.0288.52E-021.37E-061.03E-062.18E-08NoYes
rs30981691550,754A0.49−0.0108.00E-05−0.0463.81E-034.87E-064.46E-064.52E-08YesYes
rs31316101550,800A0.25−0.0079.20E-03−0.0792.98E-054.41E-063.93E-064.61E-08YesYes
rs1132942831564,346A0.100.0104.28E-020.1894.47E-063.15E-062.58E-064.64E-08YesYes
rs1169266491743,507A0.23−0.0174.46E-07−0.0367.94E-026.43E-074.75E-078.26E-09NoYes
rs1439829951743,546T0.22−0.0163.62E-06−0.0679.61E-036.33E-075.28E-073.65E-09YesYes
rs1501803551743,687A0.25−0.0158.15E-05−0.0912.39E-043.66E-073.20E-071.01E-09YesYes
rs1170862661744,077A0.730.0163.34E-070.0461.82E-021.21E-079.36E-085.38E-10YesYes
rs1433645301744,132A0.28−0.0171.16E-07−0.0481.38E-023.41E-082.56E-089.65E-11YesYes
rs1995331744,829A0.25−0.0177.16E-08−0.0481.14E-021.79E-081.33E-083.95E-11YesYes
rs1995031744,862A0.25−0.0175.86E-08−0.0491.18E-021.52E-081.12E-083.25E-11YesYes
rs126113581946,251A0.420.0074.65E-030.0671.63E-051.32E-061.15E-068.09E-09YesYes
rs20145761946,269A0.440.0061.69E-020.0718.68E-062.45E-062.09E-062.48E-08YesYes
rs28379922142,621T0.390.0133.08E-070.0372.26E-021.38E-071.06E-076.87E-10YesYes

Chr denotes chromosome; Pos, kb denotes position in kilo bases; EAF denotes frequency of the effect allele indicated in column A1

Subscripts EDU and AD indicate the estimates of the effect sizes (β) and p value (P) from published genome-wide association studies of education and Alzheimer’s disease, respectively.

Columns , , and show p values from the pleiotropic analyses using Fisher’s method and two omnibus tests, respectively. Subscripts Omni1 and Omni2 denote the results of the pleiotropic analyses using omnibus tests with Pearson correlation coefficients between Alzheimer’s disease and education r = −0.03 and r = −0.30, respectively.

Column Plt indicates pleiotropy (yes) defined based on Fisher’s method. Column AH indicates antagonistic pleiotropy (yes).

More details are given in Supplementary Table S1.

Genome-wide significant pleiotropic associations for SNPs, which did not attain genome-wide significance in the univariate GWAS of education or Alzheimer’s disease. Chr denotes chromosome; Pos, kb denotes position in kilo bases; EAF denotes frequency of the effect allele indicated in column A1 Subscripts EDU and AD indicate the estimates of the effect sizes (β) and p value (P) from published genome-wide association studies of education and Alzheimer’s disease, respectively. Columns , , and show p values from the pleiotropic analyses using Fisher’s method and two omnibus tests, respectively. Subscripts Omni1 and Omni2 denote the results of the pleiotropic analyses using omnibus tests with Pearson correlation coefficients between Alzheimer’s disease and education r = −0.03 and r = −0.30, respectively. Column Plt indicates pleiotropy (yes) defined based on Fisher’s method. Column AH indicates antagonistic pleiotropy (yes). More details are given in Supplementary Table S1. Of these 53 SNPs, Fisher’s method identified pleiotropic associations for 46 SNPs, for which Fisher’s p value was smaller than the p value for the association with either AD or EDU (Table 1, column Plt). Pleiotropic GW significance in this test was achieved for 10 of 46 SNPs located on chromosomes 2, 6, 7, and 17. For 45 of 46 pleiotropic SNPs (except rs12006296), p values in the univariate analysis attained nominal significance (p < 0.05). In contrast, for the remaining seven of 53 SNPs, the univariate association with either EDU or AD was of suggestive-effect significance (0.05 < p < 0.1). Table 1 shows that signs of the univariate associations of the same alleles with AD and EDU are opposite for two of 53 SNPs only, rs17504614 and rs6952006. This is an intuitively expected relationship because it is consistent with the negative correlation between AD and EDU. Then, it is anticipated that the omnibus test penalizing for correlation between AD and EDU returns less significant estimates than Fisher’s method, which, in this case, becomes below GW level, p > 5 × 10−8. The signs of the associations of the same alleles from the remaining 51 SNPs with EDU and AD are, however, the same. This relationship is counterintuitive because of the negative correlation between AD and EDU. The same directions of genetic associations with AD and EDU and negative correlation between them imply the case of antagonistic heterogeneity [18]. This counterintuitive heterogeneity leads to increasing the significance (i.e., smaller p values), rather than decreasing, of the pleiotropic effects for the correlated traits in the omnibus test compared to Fisher’s method. This increase is modest when the correlation is small (Table 1, r = −0.03), but it is substantially larger, ranging from 1.8 to 3.2 orders of magnitude when the correlation is larger (Table 1, r = −0.30). Antagonistic heterogeneity supports pleiotropic associations for the remaining seven of 53 SNPs, which were not selected as pleiotropic using Fisher’s method.

Pleiotropic associations for SNPs which attained GW significance with EDU or AD

We identified 169 SNPs (mapped to different genes) at GW level of significance in GWAS of EDU and 37 SNPs in GWAS of AD, totaling 206 GW significant associations (Supplementary Table S2). No SNPs attained GW significance in both univariate GWAS simultaneously. For the vast majority of these SNPs, 167 of 206, the associations reaching GW significance for one trait did not attain even suggestive-effect significance (p > 0.1) for the other trait. Fisher’s method identified pleiotropic effects for 25 of 206 SNPs (Table 2). For all of them, the associations reaching GW significance for one trait also attained the nominal significance (p < 0.05) for the other trait. For eight of 25 SNPs, we also observed antagonistic heterogeneity. Such heterogeneity was seen for six other SNPs, which attained GW significance for one trait and at least suggestive-effect significance (p < 0.1) for the other trait (Supplementary Table S2). As antagonistic heterogeneity increases the significance, it supports pleiotropic associations for these six SNPs.
Table 2.

SNPs attaining genome-wide significance in the univariate GWAS of education or Alzheimer’s disease and showing pleiotropic associations with these outcomes.

Locus-SNP informationEducationAlzheimer’s diseasePleiotropic analysis
SNPChrPos, kbA1EAFβEDUPEDUβADPADPFisherPOmni1POmni2PltAH
rs1008078191,190T0.37−0.0167.88E-110.0362.58E-025.69E-118.29E-116.30E-10YesNo
rs7599488260,718T0.43−0.0172.05E-110.0372.18E-021.31E-111.96E-111.68E-10YesNo
rs3172494348,731T0.120.0264.90E-110.0641.13E-021.62E-119.89E-125.91E-15YesYes
rs34759087349,162T0.110.0261.08E-090.0533.93E-021.05E-096.78E-102.06E-12YesYes
rs7709056560,024A0.440.0146.26E-09−0.0343.16E-024.61E-096.65E-094.28E-08YesNo
rs113474297560,555T0.12−0.0231.51E-090.0483.80E-021.41E-091.94E-091.13E-08YesNo
rs6882046587,969A0.69−0.0217.92E-140.0441.03E-022.92E-144.85E-147.12E-13YesNo
rs27732587,993A0.470.0174.06E-11−0.0362.11E-022.46E-113.71E-113.24E-10YesNo
rs61104616588,164A0.50−0.0166.04E-110.0352.40E-024.10E-116.05E-114.83E-10YesNo
rs3850651588,181T0.57−0.0152.41E-090.0592.77E-041.94E-114.68E-112.85E-09YesNo
rs138002663632,474T0.800.0111.56E-020.2801.52E-085.49E-093.88E-091.00E-11YesYes
rs77212406632,578T0.74−0.0092.98E-03−0.1106.84E-095.22E-103.63E-102.62E-13YesYes
rs38900651112,759C0.580.0151.03E-08−0.0655.67E-031.43E-092.62E-094.15E-08YesNo
rs38248741195,657T0.60−0.0151.21E-080.0401.62E-024.58E-097.33E-096.83E-08YesNo
rs1122241611130,855T0.42-0.0151.17E-08−0.0421.51E-024.13E-092.91E-096.94E-12YesYes
rs414885612123,451C0.77−0.0217.73E-130.0442.23E-025.62E-138.27E-137.00E-12YesNo
rs88356212123,461C0.290.0192.66E-12−0.0541.71E-031.54E-133.26E-131.31E-11YesNo
rs5574229012123,466T0.71−0.0191.36E-120.0512.72E-031.26E-132.53E-138.08E-12YesNo
rs172730212123,633A0.73−0.0223.34E-150.0505.02E-036.64E-161.23E-153.01E-14YesNo
rs1074415012123,722A0.270.0232.10E-15−0.0469.54E-037.89E-161.32E-152.07E-14YesNo
rs196935512123,742A0.73−0.0231.39E-150.0451.12E-026.17E-161.01E-151.40E-14YesNo
rs125906541492,939A0.350.0075.86E-03−0.0974.10E-085.56E-091.01E-081.48E-07YesNo
rs620571471743,903A0.27−0.0173.67E-08−0.0461.72E-021.40E-081.01E-083.40E-11YesYes
rs1169263461743,931A0.24−0.0184.45E-08−0.0501.27E-021.26E-089.24E-092.64E-11YesYes
rs1135686791743,991A0.730.0183.03E-080.0509.67E-036.72E-094.87E-091.06E-11YesYes

Chr denotes chromosome; Pos, kb denotes position in kilo bases; EAF denotes frequency of the effect allele indicated in column A1

Subscripts EDU and AD indicate the estimates of the effect sizes (β) and p value (P) from published genome-wide association studies of education and Alzheimer’s disease, respectively.

Columns , , and show p values from the pleiotropic analyses using Fisher method and two omnibus tests, respectively. Subscripts Omni1 and Omni2 denote the results of the pleiotropic analyses using omnibus tests with Pearson correlation coefficients between Alzheimer’s disease and education r = −0.03 and r = −0.30, respectively.

Column Plt indicates pleiotropy (yes) defined based on Fisher’s method. Column AH indicates antagonistic pleiotropy (yes).

More details are given in Supplementary Table S2.

SNPs attaining genome-wide significance in the univariate GWAS of education or Alzheimer’s disease and showing pleiotropic associations with these outcomes. Chr denotes chromosome; Pos, kb denotes position in kilo bases; EAF denotes frequency of the effect allele indicated in column A1 Subscripts EDU and AD indicate the estimates of the effect sizes (β) and p value (P) from published genome-wide association studies of education and Alzheimer’s disease, respectively. Columns , , and show p values from the pleiotropic analyses using Fisher method and two omnibus tests, respectively. Subscripts Omni1 and Omni2 denote the results of the pleiotropic analyses using omnibus tests with Pearson correlation coefficients between Alzheimer’s disease and education r = −0.03 and r = −0.30, respectively. Column Plt indicates pleiotropy (yes) defined based on Fisher’s method. Column AH indicates antagonistic pleiotropy (yes). More details are given in Supplementary Table S2.

Functional enrichment analysis

Our analysis was performed for genes harboring pleiotropic and non-pleiotropic SNPs (herein referred to as pleiotropic and non-pleiotropic gene sets, respectively) separately. Pleiotropic SNPs were consistently defined based on Fisher’s method (Tables 1 and 2 and Supplementary Table S2). Overall, 75 and 195 genes were selected for the pleiotropic and non-pleiotropic SNPs, respectively. We did not include NECTIN2, TOMM40, APOE, and APOC1 genes because AD GWAS reported p values for SNPs selected in these genes as zero, and, therefore, pleiotropy could not be reliably identified using Fisher’s method. We examined gene enrichment in pathways (defined by ingenuity canonical pathways) and categories of diseases and disorders and biological functions (defined by the ingenuity molecular and cellular functions and physiological system development and function), as discussed below. We did not examine enrichment if these biological terms were represented by one gene only.

Pathways

Pathway analysis of the pleiotropic gene set identified 29 separate, but having overlapping genes, ingenuity canonical pathways, which were significant at the false discovery rate (FDR) pFDR< 0.05 (i.e., after adjustment for multiple testing [28]) (Supplementary Table S3). Twenty-eight of them were characterized by enrichment of human leukocyte antigen (HLA) genes and were mainly immune and inflammatory pathways. The remaining synaptogenesis signaling pathway is involved in synapse formation, function, and maintenance. None of the pathways were significant at pFDR < 0.05 for the set of 195 non-pleiotropic genes.

Diseases and disorders

The top five significant IPA disease and disorder categories for the non-pleiotropic gene set included cancer, gastrointestinal disease, organismal injury and abnormalities, dermatological diseases and conditions, and neurological disease (Figure 1A). Four of them, except dermatological diseases and conditions, were in the top five for the pleiotropic gene set, but with the neurological disease on the top, followed by skeletal and muscular disorders, and then by cancer, organismal injury and abnormalities, and gastrointestinal disease (Figure 1B).
Fig. 1.

Top five categories of diseases and disorders (A and B) and biological functions (C and D) enriched in the non-pleiotropic (A and C) and pleiotropic (B and D) gene sets. The x-axis shows minus log-base-10 transformed false discovery rate adjusted p value (pFDR) (i.e., q value).

Top five categories of diseases and disorders (A and B) and biological functions (C and D) enriched in the non-pleiotropic (A and C) and pleiotropic (B and D) gene sets. The x-axis shows minus log-base-10 transformed false discovery rate adjusted p value (pFDR) (i.e., q value). Disease annotation showed enrichment of cancers at different sites (with the prevalence of extracranial solid tumor and digestive organ tumor) in both non-pleiotropic and pleiotropic gene sets, although this enrichment was more pronounced in the non-pleiotropic gene set (Supplementary Tables S4 and S5). Apart from cancers, both pleiotropic and non-pleiotropic sets were enriched for the same three brain disorders (familial AD, familial encephalopathy, familial schizophrenia), hypoplasia, and inflammatory bowel diseases, specifically Crohn’s disease (Table 3).
Table 3.

Enrichment of disease and disorder sub-categories in non-pleiotropic and pleiotropic gene sets.

Non-pleiotropic setPleiotropic set
Disease and disorder sub-categoryPFisherPFDRPFisherPFDRScore
Crohn disease3.32E-061.52E-041.20E-033.34E-025.29
Inflammatory bowel disease9.32E-052.43E-039.08E-043.17E-024.11
Familial Alzheimer’s disease6.69E-041.25E-021.01E-025.82E-023.14
Familial encephalopathy6.89E-041.27E-021.09E-033.34E-023.37
Syndromic encephalopathy7.17E-041.31E-025.10E-034.62E-023.22
Familial schizophrenia2.55E-033.41E-024.85E-034.46E-022.82
Hypoplasia3.59E-034.32E-024.24E-034.11E-022.75
Chronic inflammatory disorder4.60E-035.03E-024.23E-034.11E-022.68

is p value from the Fisher test; is FDR adjusted p value.

Score is IPA score defined as sum of minus log-base-ten transformed FDR adjusted p values.

Enrichment of disease and disorder sub-categories in non-pleiotropic and pleiotropic gene sets. is p value from the Fisher test; is FDR adjusted p value. Score is IPA score defined as sum of minus log-base-ten transformed FDR adjusted p values. Annotation of non-cancer diseases and disorders identified 38 sub-categories enriched (pFDR < 0.05) only in the non-pleiotropic gene set (Table 4 and Supplementary Table S4). Brain disorders, including late-onset AD, were at the top. In addition, we observed enrichment of neurodevelopmental disorders, such as congenital malformation of the brain, autism spectrum disorder (ASD), and mental retardation, which can adversely affect cognitive function and academic performance. The non-pleiotropic gene set was also enriched for conditions related to abnormal organ development (e.g., dysgenesis, aplasia, or hypoplasia) and several specific disorders (e.g., amyloidosis, microangiopathy, lesioning of the aorta, early-onset obesity).
Table 4.

Top 20 disease and disorder sub-categories enriched either in the non-pleiotropic or pleiotropic gene set.

Non-pleiotropic setPleiotropic set
Disease/disorder sub-categoryPFisherPFDRDisease/disorder sub-categoryPFisherPFDR
Cerebral disorder2.11E-102.75E-08Progressive neuropathy1.00E-071.23E-04
Late-onset Alzheimer’s disease4.17E-093.41E-07Progressive neuromuscular disease5.22E-081.23E-04
Cognitive impairment1.77E-056.08E-04Neuromuscular disease2.21E-071.81E-04
Autism or intellectual disability3.18E-059.93E-04Progressive motor neuropathy5.28E-072.58E-04
Congenital malformation of brain3.27E-051.00E-03Multiple sclerosis9.44E-073.20E-04
Congenital neurological disorder3.54E-051.07E-03Progressive neurological disorder6.77E-061.20E-03
Mental retardation5.21E-051.49E-03Disorder of basal ganglia1.37E-051.97E-03
Cockayne syndrome type I6.83E-051.87E-03Progressive parkinsonism1.86E-052.40E-03
Autism spectrum disorder or intellectual disability8.44E-052.24E-03Susceptibility to multiple sclerosis2.93E-052.99E-03
Nonspecific mental retardation2.36E-045.53E-03Movement disorders2.73E-052.99E-03
Dysgenesis2.61E-045.93E-03Parkinson’s disease1.26E-049.92E-03
Amyloidosis3.98E-048.37E-03Creutzfeldt-Jakob disease1.46E-041.03E-02
Aplasia or hypoplasia4.17E-048.61E-03Hypersomnia1.46E-041.03E-02
Alzheimer disease4.57E-049.19E-03Insulin-dependent diabetes mellitus1.47E-041.03E-02
Microangiopathy6.16E-041.19E-02Cirrhosis of liver1.64E-041.12E-02
Aplasia6.32E-041.22E-02Severe Alzheimer’s disease2.04E-041.24E-02
Early-onset obesity6.68E-041.25E-02Systemic lupus erythematosus2.37E-041.42E-02
Lesioning of aorta6.72E-041.25E-02Contact dermatitis or eczema2.83E-041.61E-02
Abnormality of cerebral cortex7.60E-041.38E-02Severe COVID-193.13E-041.74E-02
Non-ketotic hyperglycinemia1.00E-031.73E-02Primary biliary cirrhosis3.93E-041.96E-02

is p value from the Fisher test; is false discovery rate adjusted p value.

Top 20 disease and disorder sub-categories enriched either in the non-pleiotropic or pleiotropic gene set. is p value from the Fisher test; is false discovery rate adjusted p value. In the pleiotropic gene set, we identified 67 disease and disorder sub-categories with enrichment at pFDR < 0.05 (Table 4 and Supplementary Table S5). Top conditions were related to progressive neurological and neuromuscular diseases and movement disorders, including progressive motor neuropathy (PMN), multiple sclerosis (MS), progressive parkinsonism, Creutzfeldt-Jakob disease, and severe AD, which are often immune-mediated. Also, this set was characterized by sleep disorder (hypersomnia) and specific autoimmune conditions, e.g., insulin-dependent diabetes mellitus, systemic lupus erythematosus, primary biliary cirrhosis, and rheumatoid arthritis. Enrichment of the immune-mediated conditions was mainly driven by the HLA locus genes.

Biological functions

The analysis of biological functions showed that tissue development was the only common category in the top five categories for the non-pleiotropic and pleiotropic gene sets (Figure 1C and 1D). Top categories of biological functions highlighted nervous system development for the non-pleiotropic gene set and cellular assembly and organization linked to cellular function and maintenance for the pleiotropic one. Comparative analysis of biological functions in the pleiotropic (Supplementary Table S4) and non-pleiotropic (Supplementary Table S5) gene sets identified 20 common functional annotations related to brain development and synapse formation, organization of the cytoskeleton, organismal death, spatial learning, and nest-building behavior (Table 5).
Table 5

Biological functions enriched in both the non-pleiotropic and pleiotropic gene sets.

Non-pleiotropic setPleiotropic set
Biological functionsPFisherPFDRPFisherPFDRScore
Development of CNS1.68E-091.50E-071.50E-026.95E-027.98
Development of neurons2.18E-081.66E-066.26E-042.54E-027.38
Microtubule dynamics7.07E-074.18E-053.44E-041.87E-026.11
Organization of cytoplasm5.85E-073.54E-057.18E-042.74E-026.01
Morphogenesis of neurons4.85E-073.01E-053.30E-033.40E-025.99
Formation of cellular protrusions3.09E-071.99E-057.58E-035.35E-025.97
Organization of cytoskeleton1.79E-069.02E-056.46E-042.55E-025.64
Neuritogenesis1.38E-067.23E-051.03E-025.91E-025.37
Guidance of axons2.62E-058.48E-046.31E-034.62E-024.41
Spatial learning5.80E-051.64E-038.73E-035.51E-024.04
Organismal death1.31E-043.25E-039.21E-043.17E-023.99
Excitatory postsynaptic potential1.49E-043.67E-032.68E-033.34E-023.91
Neurotransmission5.93E-041.15E-023.08E-033.34E-023.42
Development of CNS cells7.63E-041.38E-027.64E-042.87E-023.40
Development of head3.47E-047.54E-031.14E-026.48E-023.31
Nest building behavior1.93E-032.85E-024.02E-033.96E-022.95
Quantity of filaments2.50E-033.40E-021.80E-033.34E-022.94
Development of cerebral cortex2.59E-033.45E-025.33E-034.62E-022.80
Quantity of cells4.48E-034.93E-022.72E-033.34E-021.48
Developmental process of synapse3.81E-034.47E-021.52E-026.95E-021.16

is p value from the Fisher test; is FDR adjusted p value.

Score is IPA score defined as sum of minus log-base-ten transformed FDR adjusted p values.

Biological functions enriched in both the non-pleiotropic and pleiotropic gene sets. is p value from the Fisher test; is FDR adjusted p value. Score is IPA score defined as sum of minus log-base-ten transformed FDR adjusted p values. Top characteristic sub-categories for the pleiotropic gene set included specific microtubule-related terms (e.g., quantity of microtubules), formation of senile plaques, specific behaviors (e.g., grooming, emotional behaviors), early gonadogenesis (e.g., elongation of gonadal cell lines), immune-related processes, heavy metal and water transport, synaptic events, etc. (Table 6). Apart from cell proliferation of tumor cell lines (pFDR = 8.36 × 10−5) (Supplementary Table S5), top specific terms for the non-pleiotropic gene set were related to the development of the brain and neuronal morphology, cell viability and neuronal cell death, and the process of transcription (Table 6).
Table 6.

Top 25 biological functions enriched either in the non-pleiotropic or pleiotropic gene set.

Non-pleiotropic setPleiotropic set
Biological functionsPFisherPFDRBiological functionsPFisherPFDR
Formation of brain2.20E-061.07E-04Quantity of microtubules9.29E-057.84E-03
Cell movement of neurons7.03E-062.81E-04Formation of senile plaques9.73E-057.94E-03
Morphology of nervous tissue7.93E-063.15E-04Dissociation of microtubules1.46E-041.03E-02
Differentiation of neuroglia8.78E-063.44E-04Grooming1.81E-041.20E-02
Cell viability1.33E-054.89E-04Elongation of gonadal cell lines2.04E-041.24E-02
Morphology of nervous system1.46E-055.25E-04Emotional behavior2.65E-041.55E-02
Transcription1.52E-055.46E-04Lack of CD4+ T-lymphocytes4.34E-042.08E-02
Cell viability of neurons1.58E-055.61E-04Differentiation of natural T-regulatory cells4.34E-042.08E-02
Shape change of neurons1.59E-055.61E-04Hydrolysis of phosphatidylinositol phosphate5.29E-042.23E-02
Abnormal morphology of cerebral neocortex1.61E-055.63E-04Instability of microtubules6.33E-042.54E-02
Abnormal morphology of commissure1.70E-055.88E-04Morphology of thymus gland9.87E-043.34E-02
Morphology of neurons1.83E-056.21E-04Beat of cells1.14E-033.34E-02
Differentiation of nervous system1.87E-056.30E-04Export of heavy metal1.14E-033.34E-02
Cell survival1.91E-056.36E-04Uptake of water1.14E-033.34E-02
Morphology of somatosensory cortex1.91E-056.36E-04Function of synapse1.29E-033.34E-02
Migration of neurons2.34E-057.68E-04Homeostasis of leukocytes1.67E-033.34E-02
Formation of rhombencephalon2.84E-058.98E-04Abnormal morphology of thymus gland1.72E-033.34E-02
Survival of cerebellar cortex cells2.98E-059.34E-04Abnormal morphology of iris1.79E-033.34E-02
Abnormal morphology of forebrain3.23E-051.00E-03Fear conditioning1.79E-033.34E-02
Neuronal cell death3.64E-051.09E-03Quantity of amacrine cells1.79E-033.34E-02
Abnormal morphology of brain3.87E-051.15E-03Abnormal morphology of lens fiber cells2.37E-033.34E-02
Branching of neurites4.03E-051.19E-03Anxiety-like behavior2.38E-033.34E-02
Collapse of growth cone4.05E-051.19E-03Development of body axis2.44E-033.34E-02
Necrosis4.07E-051.19E-03Release of neurotransmitter2.48E-033.34E-02
Development of metencephalon4.27E-051.24E-03Differentiation of regulatory T lymphocytes2.72E-033.34E-02

is p value from the Fisher test; is false discovery rate adjusted p value.

Top 25 biological functions enriched either in the non-pleiotropic or pleiotropic gene set. is p value from the Fisher test; is false discovery rate adjusted p value.

Discussion

Here, we comprehensively examined pleiotropic predisposition to AD and EDU using Fisher’s method and omnibus test applied to summary statistics reported in large-scale univariate GWAS of AD [19] and EDU [20]. Fisher’s method performs pleiotropic meta-analysis by combining probabilities of AD and EDU for carriers of the risk variants, and, therefore, it disregards correlation between phenotypes. The omnibus test adjusts the estimates for such correlation. Accordingly, Fisher’s method can be considered as a reference, and comparative analysis of the results using this method and the omnibus test helps in evaluating the role of correlation between AD and EDU. Meta-analysis of pleiotropic associations for SNPs that did not attain GW significance in the univariate GWAS of EDU or AD (5 × 10−8 < p < 0.1) identified 53 SNPs for which pleotropic significance achieved GW level using Fisher’s method or the omnibus test. The vast majority of them, 46 of 53 SNPs (86.8%), showed pleiotropic signals using Fisher’s method, but only 10 of these 46 SNPs attained pleiotropic GW significance. A commonly anticipated role of correlation between phenotypes is that it attenuates pleiotropic association because of overlapped signals due to either biological pleiotropy (influence of one genetic variant on more than one trait [29]) or mediated pleiotropy (indirect association with a downstream phenotype through an intermediate phenotype [29]). Previously, we showed that correlation between phenotypes might not necessarily attenuate pleiotropic signals but can also strengthen them [18] (see also “Pleiotropic meta-analysis” section in Methods). Despite counter-intuitiveness, this phenomenon, called antagonistic genetic heterogeneity, appears to be common in the genetics of complex (heterogeneous) traits because genetic predisposition to them may not be driven by the same mechanism as their correlation [17]. Here, we show that the antagonistic genetic heterogeneity increases the significance of the pleiotropic associations for 51 SNPs, making all of them attain the GW level, and suggests additional pleiotropic associations. Thus, contrary to the common expectation, Fisher’s method may provide more conservative estimates of pleiotropy than the omnibus test. In contrast, Fisher’s method identified pleiotropic associations only for 25 of 206 SNPs (12.1%), which attained the GW significance in prior GWAS of EDU or AD. Also, the antagonistic heterogeneity was less pronounced in this set of SNPs affecting eight of 25 pleiotropic SNPs. Larger fractions of pleiotropic associations and antagonistic heterogeneity for SNPs, which did not attain GW significances in the univariate GWAS of AD and EDU compared to those which attained such significances, support a role of heterogeneity of genetic architecture of AD and EDU driven by different biological mechanisms. Our functional enrichment analysis of genes harboring pleiotropic and non-pleiotropic SNPs shows both common and specific mechanisms associated with diseases and bio-functions for these two sets. The non-pleiotropic and pleiotropic gene sets were characterized by enrichment for cancers at different sites (although this enrichment was more pronounced in the non-pleiotropic gene set), some familial brain disorders, including familial AD, and Crohn’s disease (Figures 1A and 1B and Table 3). Studies report that chronic inflammation may be connected to neurodegeneration and increase cancer risk [30, 31]. For example, chronic inflammatory conditions of the digestive system increase the risk of developing gastrointestinal malignancies [32]. Patients with inflammatory bowel disease showed positive association with dementia including AD and Parkinson’s disease (PD) [33, 34]. Prior studies reported genetic overlap between AD and immune-mediated diseases including Crohn’s disease [35]. Common bio-functions in the pleiotropic and non-pleiotropic gene sets were related to the development of the brain and synapse formation, organization of the cytoskeleton, organismal death, spatial learning, and nest-building behavior (Table 5). Processes related to the organization of the cytoskeleton (e.g., microtubule dynamics) play roles during the development of neuronal morphology, synapse formation and maintenance, and neurodegeneration [36]. Spatial learning is necessary for orientation in space and the formation of episodic memories, which is the most severely affected aspect of memory in AD [37]. AD has been characterized by spatial disorientation presented from its early stages and degradation with disease progression [38, 39]. Nest building is related to social behavior and characterizes activities of daily living, which are impaired in people affected by progressive neurodegenerative disorders such as AD and PD [40]. Impairment in nest building is a characteristic feature of multiple transgenic mouse AD models [41]. Also, children with neurodevelopmental disorders usually have poorer activities of daily living performance [42, 43]. In addition to enrichment of multiple cancer types, the non-pleiotropic gene set was characterized by gene enrichment in age-associated cognitive impairment and late-onset AD, along with neurodevelopmental disorders, including congenital encephalopathy, ASD, and mental retardation (Table 4 and Supplementary Table S4). Both cancer and neurodegenerative diseases such as late-onset AD are common in aging, and they may have common underlying age-related mechanisms. Epidemiological studies show, however, that the relationship between these diseases is complex [44-47]. Enrichment of cancers is in line with the close relationship between cancer and developmental biology. Indeed, embryonic development is characterized by synergistic regulation when cells become organized in functional structures, whereas cancer is characterized by dysregulation of well-behaved structures, i.e., by disorder [48, 49]. It might be hypothesized that dysregulation of the transcriptional programs during embryonal development causes abnormal morphology and developmental disorders and leads to dysregulation in late-life, causing tumorigenesis and cancer progression. Neurodevelopmental disorders can lead to behavioral and learning problems and visual and hearing impairments and directly affect mental processes by limiting educational opportunities and affecting academic achievements. Analysis of bio-functions for the non-pleiotropic gene set highlighted morphological development of the nervous system, cell survival and death, and transcription process (Table 6 and Supplementary Table S4). Terms related to the morphology of the nervous system indicate anomalies of brain structure and alterations in neuronal morphology, which can contribute to neurodevelopmental disorders and neurodegenerative diseases. For example, a change of the physical structure and the connectivity in the brain was shown in ASD and disorders associated with intellectual disability [50, 51]. Structural changes in specific brain regions and altered neuronal morphology is also characteristic for AD patients [52-54]. Neuronal cell viability is important in normal and impaired brain development and during adult neurogenesis. Neuronal cell death is necessary to optimize brain connectivity during development, and it affects cognitive abilities. It is also associated with neurodevelopmental and psychiatric disorders such as schizophrenia and ASD and can occur in neurodegenerative disorders, including AD [55, 56]. Transcription, the first step of gene expression, highlights the role of transcriptional control in gene regulation. Transcriptional factors are especially important during development. The activity of the transcription factors is linked to multiple neurological disorders and developmental pathologies [57]. Dysregulation of the transcriptional programs is a hallmark of cancer [58]. The pleiotropic gene set was characterized by enrichment of immune and inflammatory pathways driven by HLA genes (Supplementary Table S3). This is in line with enrichment of a number of systemic or organ-specific autoimmune diseases including MS, systemic lupus erythematosus, and type 1 diabetes. In this set, we identified enrichment of neurologic and neuromuscular diseases and movement disorders along with immune-mediated conditions (Table 4 and Supplementary Table S5). A broad spectrum of progressive neurodegenerative diseases affecting various organ systems was enriched in this gene set, including slowly (e.g., MS, PD, severe AD) and rapidly (e.g., Creutzfeldt-Jakob disease) progressive conditions. Enrichment of bio-functions in the pleiotropic gene set was in line with diseases and disorders characteristic for this set (Table 6 and Supplementary Table S5). For example, enrichment of specific microtubule-related terms (e.g., quantity of microtubules) emphasizes the role of microtubules, which are a highly dynamic part of the cell cytoskeleton playing roles in maintaining neuronal functions and neurodegenerative processes [59]. Microtubules network is a dynamic regulator of skeletal muscle function [60]. Axonal microtubule loss correlates with progressive motor neuron degeneration in motor neuron diseases such as PMN [61]. Microtubule dysfunction is common in many neurodegenerative diseases and movement disorders, including AD and PD [62, 63]. In particular, neurofibrillary tangles, a hallmark of AD, are abnormal accumulations of the microtubule-associated protein tau in a hyperphosphorylated state [63, 64]. Enrichment of specific behaviors such as grooming, emotional behavior, and stress-driven fear- and anxiety-like behavior is consistent with the results from animal models of AD and PD. For example, progressive degeneration in grooming due to impairments in motor function is considered a symptom of PD and basal ganglia disorders [65, 66]. Emotional symptoms such as stress, anxiety, fear, and depression are common for neurodegenerative diseases, including AD, PD, and MS [67-69]. Our functional analysis highlights the role of T lymphocytes in immune regulation and links the immune system with neurological disorders (including AD and MS) and the set-specific autoimmune diseases [70-72]. Phosphoinositides signaling (e.g., hydrolysis of phosphatidylinositol phosphate) has several critical roles in the nervous system, including synaptic transmission and cytoskeletal function in neurons [73]. Phosphatidylinositol levels are also affected in AD [74]. Heavy metal toxicity (e.g., export of heavy metal) has been linked to neurological problems and progressive neurological disorders, including AD, PD, and MS [75]. In addition, microtubules play important roles in lens fiber cell functions (e.g., abnormal morphology of lens fiber cells) [76]. Vision problems are the source of behavioral impairments, which impact learning opportunities affecting thus cognition. Despite the rigor of this study, we acknowledge its limitations. The first is the use of summary statistics rather than individual-level data. Summary statistics limit the ability to accurately model the role of correlation between AD and EDU in pleiotropic predisposition to these phenotypes because this correlation was not reported in those studies. This limitation was partly offset by estimating the phenotypic correlation between AD and EDU from three independent studies available to us and the genetic correlation between them evaluated from the reported summary statistics. The second is the lack of replication statistics from independent GWAS. This limitation is partly offset by leveraging the results of large-scale GWAS. The third is that different number of genes in the pleiotropic and non-pleiotropic sets (75 vs. 195) may affects our comparative functional analysis. Thus, leveraging summary statistics from two large-scale univariate GWAS of AD and EDU, we identified pleiotropic associations of SNPs from multiple loci with both these phenotypes. We showed that a large fraction of the pleiotropic associations was affected by a counterintuitive phenomenon of antagonistic genetic heterogeneity, which appeared to be widespread in the genetics of complex traits. Our comparative functional enrichment analysis of pleiotropic and non-pleiotropic gene sets identified potential differences in biological mechanisms of AD and EDU. The non-pleiotropic gene set was mainly characterized by late-onset AD along with neurodevelopmental disorders and processes related to brain development and neuronal morphology. The pleiotropic gene set was associated with processes characteristic for a broad spectrum of progressive neuromuscular and neurologic diseases and immune-mediated conditions. (XLSX 25 kb) (XLSX 63 kb) (XLSX 12 kb) (XLSX 67 kb) (XLSX 31 kb) (DOCX 22 kb)
  58 in total

1.  Brain networks associated with cognitive reserve in healthy young and old adults.

Authors:  Yaakov Stern; Christian Habeck; James Moeller; Nikolaos Scarmeas; Karen E Anderson; H John Hilton; Joseph Flynn; Harold Sackeim; Ronald van Heertum
Journal:  Cereb Cortex       Date:  2005-04       Impact factor: 5.357

2.  Incidence of Dementia and Alzheimer Disease Over Time: A Meta-Analysis.

Authors:  Sujuan Gao; Heather N Burney; Chris M Callahan; Christianna E Purnell; Hugh C Hendrie
Journal:  J Am Geriatr Soc       Date:  2019-06-20       Impact factor: 5.562

3.  Trends in the incidence and prevalence of Alzheimer's disease, dementia, and cognitive impairment in the United States.

Authors:  Walter A Rocca; Ronald C Petersen; David S Knopman; Liesi E Hebert; Denis A Evans; Kathleen S Hall; Sujuan Gao; Frederick W Unverzagt; Kenneth M Langa; Eric B Larson; Lon R White
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

4.  New insights into the dementia epidemic.

Authors:  Eric B Larson; Kristine Yaffe; Kenneth M Langa
Journal:  N Engl J Med       Date:  2013-11-27       Impact factor: 91.245

Review 5.  Cognitive reserve in ageing and Alzheimer's disease.

Authors:  Yaakov Stern
Journal:  Lancet Neurol       Date:  2012-11       Impact factor: 44.182

Review 6.  Brain reserve hypothesis in dementia.

Authors:  Laura Fratiglioni; Hui-Xin Wang
Journal:  J Alzheimers Dis       Date:  2007-08       Impact factor: 4.472

7.  Risk-reducing effect of education in Alzheimer's disease.

Authors:  Sigrid Botne Sando; Stacey Melquist; Ashley Cannon; Michael Hutton; Olav Sletvold; Ingvild Saltvedt; Linda R White; Stian Lydersen; Jan Aasly
Journal:  Int J Geriatr Psychiatry       Date:  2008-11       Impact factor: 3.485

8.  Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.

Authors:  R Katzman; R Terry; R DeTeresa; T Brown; P Davies; P Fuld; X Renbing; A Peck
Journal:  Ann Neurol       Date:  1988-02       Impact factor: 10.422

9.  Racial and ethnic estimates of Alzheimer's disease and related dementias in the United States (2015-2060) in adults aged ≥65 years.

Authors:  Kevin A Matthews; Wei Xu; Anne H Gaglioti; James B Holt; Janet B Croft; Dominic Mack; Lisa C McGuire
Journal:  Alzheimers Dement       Date:  2018-09-19       Impact factor: 21.566

Review 10.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission.

Authors:  Gill Livingston; Jonathan Huntley; Andrew Sommerlad; David Ames; Clive Ballard; Sube Banerjee; Carol Brayne; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Sergi G Costafreda; Amit Dias; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Mika Kivimäki; Eric B Larson; Adesola Ogunniyi; Vasiliki Orgeta; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam
Journal:  Lancet       Date:  2020-07-30       Impact factor: 79.321

View more
  1 in total

1.  Editorial: New developments in understanding brain and cerebromicrovascular aging: Toward prevention of vascular cognitive impairment and Alzheimer's disease.

Authors:  Madison Sanford; Sharon Negri; Stefano Tarantini
Journal:  Front Aging Neurosci       Date:  2022-09-16       Impact factor: 5.702

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.